This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Belantamab mafodotin for relapsed / refractory multiple myeloma – Fourth line

< Back

Belantamab mafodotin for relapsed / refractory multiple myeloma – Fourth line


Cancer and Palliative Care

August 2019

Belantamab mafodotin is in clinical development for the treatment of multiple myeloma (MM) in patients who are refractory or have relapsed to prior treatments. MM is a rare, incurable cancer of the plasma cells in the bone marrow where large amounts of abnormal plasma cells are produced and interfere with the production of red and white blood cells and platelets. People with MM will experience periods of time without symptoms followed by periods when the illness comes back (‘relapsed’ MM). Eventually the periods without symptoms will shorten and the illness will become immune to the drugs given to treat it (‘refractory’ MM).
Belantamab mafodotin is a first-in-class therapy delivered via intravenous infusion. This medicine is an antibody drug conjugate comprising a B cell maturation antigen (BCMA)-targeting monoclonal antibody that delivers a cytotoxin (cysMMAF) to abnormal plasma cells, which interferes with the cell’s ability to divide and grow and encourages the immune system to attack the affected cells, slowing the progression of the disease. If licensed, belantamab mafodotin has the potential to improve outcomes in patients that have already received prior treatments but their myeloma has come back.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts